<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-12-25</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719685/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Multiple Sclerosis: Glial Cell Diversity in Time and Space</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719685-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Multiple sclerosis (MS) is the most prevalent human inflammatory disease of the central nervous system with demyelination and glial scar formation as pathological hallmarks. Glial cells are key drivers of lesion progression in MS with roles in both tissue damage and repair depending on the surrounding microenvironment and the functional state of the individual glial subtype. In this review, we describe recent developments in the context of glial cell diversity in MS summarizing key findings &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719866/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Pd(0)/Pd(II) Electromerism Triggered by Lewis Base Coordination to a Redox-Active Silicon Z-Type Ligand</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719866-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Electromerism (aka. valence tautomerism) corresponds to the switching of electronic distributions between redox-active ligands and central elements. While this phenomenon is well established for several transition metals, the Pd(0)/Pd(II) couple could not yet be involved due to the high energy of the Pd(0) state. In this study, we present Pd(0)/Pd(II) electromerism by using a redox-active bis(phosphanyl-amidophenolato)silane. Strong silicon-based Z-type interaction stabilizes the Pd(0) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39720154/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">How to conduct and report checking transitivity and inconsistency in network-meta-analysis: a narrative review including practical worked examples, code and source data for sports and exercise medicine researchers</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39720154-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The use of network meta-analysis (NMA) in sport and exercise medicine (SEM) research continues to rise as it enables the comparison of multiple interventions that may not have been assessed in a single randomised controlled trial. NMA can then inform clinicians on potentially better interventions. Despite the increased use of NMA, we have observed that in the SEM field, a key challenge for author groups can be the assessment and reporting of key assumptions, in particular transitivity &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39720562/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39720562-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: An intensified, multimodal treatment approach including RP can lead to excellent survival outcomes in patients with newly diagnosed omPCa. Patients requiring chemotherapy have most likely a more aggressive disease and therefore a more rapid tumor progression. Future studies to identify markers for risk stratification in patients with omPCa are therefore &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39720600/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">AI education for clinicians</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39720600-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Rapid advancements in medical AI necessitate targeted educational initiatives for clinicians to ensure AI tools are safe and used effectively to improve patient outcomes. To support decision-making among stakeholders in medical education, we propose three tiers of medical AI expertise and outline the challenges for medical education at different educational stages. Additionally, we offer recommendations and examples, encouraging stakeholders to adapt and shape curricula for their &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39720612/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Novel type 2 diabetes prediction score based on traditional risk factors and circulating metabolites: model derivation and validation in two large cohort studies</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39720612-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: We aimed to evaluate the incremental predictive value of metabolomic biomarkers for assessing the 10-year risk of type 2 diabetes when added to the clinical Cambridge Diabetes Risk Score &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39720846/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Establishing the Research Priorities of ADHD Professionals: An International Delphi Study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39720846-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: These results can inform an ADHD research agenda which represents the views of the individuals from major ADHD professional groups internationally. Parallel work is needed focusing on research priorities from the perspective of ADHD &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39720906/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Predicting Type 2 Diabetes and Testosterone Effects in high-risk Australian men: Development and external validation of a 2 year risk model</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39720906-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Baseline HbA1c and 2-hour OGTT glucose predict incident type 2 diabetes at 2 years in high-risk men, with risk modified independently by Testosterone treatment. Men with HbA1c≥5.6% (38mmol/mol) benefit most from Testosterone treatment, beyond a lifestyle &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39716240/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241224170749&amp;v=2.18.0.post9&#43;e462414">AttenhERG: a reliable and interpretable graph neural network framework for predicting hERG channel blockers</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39716240-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241224170749-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cardiotoxicity, particularly drug-induced arrhythmias, poses a significant challenge in drug development, highlighting the importance of early-stage prediction of human ether-a-go-go-related gene (hERG) toxicity. hERG encodes the pore-forming subunit of the cardiac potassium channel. Traditional methods are both costly and time-intensive, necessitating the development of computational approaches. In this study, we introduce AttenhERG, a novel graph neural network framework designed to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39716240/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241225170605&amp;v=2.18.0.post9&#43;e462414">AttenhERG: a reliable and interpretable graph neural network framework for predicting hERG channel blockers</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39716240-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241225170605-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cardiotoxicity, particularly drug-induced arrhythmias, poses a significant challenge in drug development, highlighting the importance of early-stage prediction of human ether-a-go-go-related gene (hERG) toxicity. hERG encodes the pore-forming subunit of the cardiac potassium channel. Traditional methods are both costly and time-intensive, necessitating the development of computational approaches. In this study, we introduce AttenhERG, a novel graph neural network framework designed to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39716471/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Modeling cancer-microbiome interactions in vitro: A guide to co-culture platforms</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39716471-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The biology of cancer is characterized by an intricate interplay of cells originating not only from the tumor mass, but also its surrounding environment. Different microbial species have been suggested to be enriched in tumors and the impacts of these on tumor phenotypes is subject to intensive investigation. For these efforts, model systems that accurately reflect human-microbe interactions are rapidly gaining importance. Here we present a guide for selecting a suitable in vitro &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39716692/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">IMPACT OF REPEAT HLA MISMATCHES ON KIDNEY GRAFT SURVIVAL: A CONTEMPORARY COLLABORATIVE TRANSPLANT STUDY (CTS) ANALYSIS</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39716692-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Repeat HLA mismatches (RMM) have been historically associated with an increased risk of graft loss after repeat kidney transplantation, in particular HLA-DR RMM in sensitized recipients. As routine use of sensitive assays can at present prevent the transplantation of RMM in hosts with donor-specific antibodies, we hypothesized that RMM would no longer be associated with graft loss. We performed a registry analysis of the Collaborative Transplant Study database including 6711 patients &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39716718/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">&#39;Home inspections&#39; for life sciences companies going public before clinical proof-of-concept</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39716718-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    For the period from 2010 to 2021, we have observed a phenomenon of life sciences companies conducting Initial Public Offerings (IPOs) without any assets that have demonstrated clinical proof-of-concept (POC). Ideally, this area of investment is targeted by investors with the knowledge and resources to assess the probability of success of such early-stage programs based upon adequately planned and performed due diligence. Our analysis of this trend calls for the establishment of a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39716918/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39716918-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Immune checkpoint blockers have substantially improved prognosis of melanoma patients, nevertheless, resistance remains a significant problem. Here, intrinsic and extrinsic factors in the tumor microenvironment are discussed, including the expression of alternative immune checkpoints such as lymphocyte activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). While most studies focus on immune cell expression of these proteins, we investigated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717184/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Definition of a framework for volumetric modulated arc therapy plan quality assessment with integration of dose-, complexity-, and robustness metrics</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717184-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The developed framework enables early detection of sub-optimal, complex and non-robust treatment plans. The predictive model can be used when robustness evaluations are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717226/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Short-term effect of temperature and precipitation on the incidence of West Nile Neuroinvasive Disease in Europe: a multi-country case-crossover analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717226-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: In recent years, Europe has experienced several outbreaks of West Nile Virus (WNV), a mosquito-borne pathogen. This study aims to quantify the impact of weekly mean temperature and cumulative precipitation on human cases of West Nile Neuroinvasive Disease (WNND), to assess the feasibility of climate-informed early warning systems for severe forms of WNV &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717364/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Multidisciplinary consensus-based statement on the current role of middle meningeal artery embolization (MMAE) in chronic SubDural hematoma (cSDH)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717364-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Middle Meningeal Artery Embolization (MMAE) in patients with chronic SubDural Hematoma (cSDH) is a novel treatment approach, albeit the specific role of MMAE in the treatment of cSDH is not yet &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717398/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241224170749&amp;v=2.18.0.post9&#43;e462414">Deep clustering representation of spatially resolved transcriptomics data using multi-view variational graph auto-encoders with consensus clustering</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717398-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241224170749-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The rapid development of spatial transcriptomics (ST) technology has provided unprecedented opportunities to understand tissue relationships and functions within specific spatial contexts. Accurate identification of spatial domains is crucial for downstream spatial transcriptomics analysis. However, effectively combining gene expression data, histological images and spatial coordinate data to identify spatial domains remains a challenge. To this end, we propose STMVGAE, a novel &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717398/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241225170605&amp;v=2.18.0.post9&#43;e462414">Deep clustering representation of spatially resolved transcriptomics data using multi-view variational graph auto-encoders with consensus clustering</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717398-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241225170605-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The rapid development of spatial transcriptomics (ST) technology has provided unprecedented opportunities to understand tissue relationships and functions within specific spatial contexts. Accurate identification of spatial domains is crucial for downstream spatial transcriptomics analysis. However, effectively combining gene expression data, histological images and spatial coordinate data to identify spatial domains remains a challenge. To this end, we propose STMVGAE, a novel &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717535/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Evaluation of Pelvic MRI-to-CT Deformable Registration for Adaptive MR-Guided Particle Therapy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717535-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: This work shows a good agreement on the DIR quality achieved with ANACONDA for the structures in the beams' path. By comparing the R80% generated with ANACONDA and Elastix, we give a first quantification of the uncertainties to be considered in an online MRI-guided particle therapy workflow for pelvic &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717677/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Exploring cytokine outputs for &lt;em&gt;ex vivo&lt;/em&gt; diagnostics in drug reaction with eosinophilia and systemic symptoms (DRESS)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717677-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In patients where the early response has suggested a TH2 response such as DRESS, IL-4 and IL-5 cytokine outputs could present an investigational advantage, including when IFN-γ is negative. In the future, larger prospective studies are required to understand the role of varied cytokine outputs in T-cell-mediated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717677/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Exploring cytokine outputs for &lt;em&gt;ex vivo&lt;/em&gt; diagnostics in drug reaction with eosinophilia and systemic symptoms (DRESS)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717677-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In patients where the early response has suggested a TH2 response such as DRESS, IL-4 and IL-5 cytokine outputs could present an investigational advantage, including when IFN-γ is negative. In the future, larger prospective studies are required to understand the role of varied cytokine outputs in T-cell-mediated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717750/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717750-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: These results demonstrated a pivotal role of the RAS-MAPK pathway in the NB cellular response to APR-246 via the modulation of intracellular concentrations of GSH and the transport of cystine through SLC7A11, phosphorylation of Hsp27, and programmed cell death. Combining APR-246 with RAS-MAPK pathway inhibitors can, in some cases, lead to antagonistic action, which can be reversed by combining APR-246 with the clinically approved drug &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717750/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717750-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: These results demonstrated a pivotal role of the RAS-MAPK pathway in the NB cellular response to APR-246 via the modulation of intracellular concentrations of GSH and the transport of cystine through SLC7A11, phosphorylation of Hsp27, and programmed cell death. Combining APR-246 with RAS-MAPK pathway inhibitors can, in some cases, lead to antagonistic action, which can be reversed by combining APR-246 with the clinically approved drug &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717766/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717766-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Recent studies have revealed the potential of tumor-infiltrating lymphocytes (TILs) to treat solid tumors effectively and safely. However, the translation of TIL therapy for patients is still hampered by non-standardized and laborious manufacturing procedures that are expensive and produce highly variable cellular products. To address these limitations, the CliniMACS Prodigy^(®) Tumor Reactive T cell (TRT) Process has been developed. The TRT Process allows the automated isolation, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39717766/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39717766-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Recent studies have revealed the potential of tumor-infiltrating lymphocytes (TILs) to treat solid tumors effectively and safely. However, the translation of TIL therapy for patients is still hampered by non-standardized and laborious manufacturing procedures that are expensive and produce highly variable cellular products. To address these limitations, the CliniMACS Prodigy^(®) Tumor Reactive T cell (TRT) Process has been developed. The TRT Process allows the automated isolation, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718010/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">A multisite validation of brain white matter pathways of resilience to chronic back pain</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718010-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chronic back pain (CBP) is a global health concern with significant societal and economic burden. While various predictors of back pain chronicity have been proposed, including demographic and psychosocial factors, neuroimaging studies have pointed to brain characteristics as predictors of CBP. However, large-scale, multisite validation of these predictors is currently lacking. In two independent longitudinal studies, we examined white matter diffusion imaging data and pain characteristics &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718010/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">A multisite validation of brain white matter pathways of resilience to chronic back pain</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718010-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chronic back pain (CBP) is a global health concern with significant societal and economic burden. While various predictors of back pain chronicity have been proposed, including demographic and psychosocial factors, neuroimaging studies have pointed to brain characteristics as predictors of CBP. However, large-scale, multisite validation of these predictors is currently lacking. In two independent longitudinal studies, we examined white matter diffusion imaging data and pain characteristics &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718339/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review Paper</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718339-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Resection of primary tumor and liver metastases is the gold standard for colorectal cancer with liver-only metastases (CRLM). Although treatment options have expanded to enable conversion of unresectable to resectable CRLM, about 40% of patients will have definitively unresectable disease. Major advances in surgical techniques, immunosuppressive protocols and patient selection criteria for liver transplantation have resulted in improved &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718339/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review Paper</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718339-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Resection of primary tumor and liver metastases is the gold standard for colorectal cancer with liver-only metastases (CRLM). Although treatment options have expanded to enable conversion of unresectable to resectable CRLM, about 40% of patients will have definitively unresectable disease. Major advances in surgical techniques, immunosuppressive protocols and patient selection criteria for liver transplantation have resulted in improved &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718480/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Long-term outcomes of unselected patients undergoing coronary angiography according to the presence or absence of type II diabetes mellitus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718480-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In unselected patients undergoing CA, T2DM represents an independent predictor of HF-related rehospitalization, AMI- and for PCI- at 36 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718480/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Long-term outcomes of unselected patients undergoing coronary angiography according to the presence or absence of type II diabetes mellitus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718480-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In unselected patients undergoing CA, T2DM represents an independent predictor of HF-related rehospitalization, AMI- and for PCI- at 36 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Random Mating in a Hybrid Zone Between Two Putative Climate-Adapted Bird Lineages With Predicted Mitonuclear Incompatibilities</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718489-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Biochemical and evolutionary interactions between mitochondrial and nuclear genomes (&lsquo;mitonuclear interactions&rsquo;) are proposed to underpin fundamental aspects of biology including evolution of sexual reproduction, adaptation and speciation. We investigated the role of pre-mating isolation in maintaining functional mitonuclear interactions in wild populations bearing diverged, putatively co-adapted mitonuclear genotypes. Two lineages of eastern yellow robin Eopsaltria australis-putatively&hellip; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Random Mating in a Hybrid Zone Between Two Putative Climate-Adapted Bird Lineages With Predicted Mitonuclear Incompatibilities</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718489-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Biochemical and evolutionary interactions between mitochondrial and nuclear genomes (&lsquo;mitonuclear interactions&rsquo;) are proposed to underpin fundamental aspects of biology including evolution of sexual reproduction, adaptation and speciation. We investigated the role of pre-mating isolation in maintaining functional mitonuclear interactions in wild populations bearing diverged, putatively co-adapted mitonuclear genotypes. Two lineages of eastern yellow robin Eopsaltria australis-putatively&hellip; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718614/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">The &#34;specific&#34; P-glycoprotein inhibitor zosuquidar (LY335979) also weakly inhibits human organic cation transporters</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718614-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Zosuquidar (LY335979) is a widely used experimental P-glycoprotein (P-gp) inhibitor, which is commended as very potent but also as very specific for P-gp. In this in vitro and in silico study, we demonstrated for the first time that zosuquidar also inhibits organic cation transporters (OCT) 1-3, albeit less potently than P-gp. This still has to be kept in mind when zosuquidar is used to inhibit cellular efflux of P-gp substrates that are concurrently transported into the cells by OCTs. To &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718614/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">The &#34;specific&#34; P-glycoprotein inhibitor zosuquidar (LY335979) also weakly inhibits human organic cation transporters</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718614-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Zosuquidar (LY335979) is a widely used experimental P-glycoprotein (P-gp) inhibitor, which is commended as very potent but also as very specific for P-gp. In this in vitro and in silico study, we demonstrated for the first time that zosuquidar also inhibits organic cation transporters (OCT) 1-3, albeit less potently than P-gp. This still has to be kept in mind when zosuquidar is used to inhibit cellular efflux of P-gp substrates that are concurrently transported into the cells by OCTs. To &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718806/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241224170756&amp;v=2.18.0.post9&#43;e462414">Best of UEG Week 2024</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718806-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241224170756-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39718806/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Best of UEG Week 2024</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39718806-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719040/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241225170554&amp;v=2.18.0.post9&#43;e462414">Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719040-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241225170554-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    We found 18 patients with immunophenotype consistent with classic hairy cell leukemia (HCL) and BRAF mutations other than just V600E. Twelve had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n=5) or 2 (n=1) non-V600E BRAF &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719041/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241225170554&amp;v=2.18.0.post9&#43;e462414">Menin inhibitors in the treatment of acute myeloid leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719041-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241225170554-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities. Menin inhibitors have emerged as a promising therapeutic approach, targeting key genetic drivers of AML such as KMT2A rearrangements and NPM1 mutations. Here, we review the clinical value of menin inhibitors, highlighting &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719042/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241225170554&amp;v=2.18.0.post9&#43;e462414">How I Treat AML relapse after allogeneic HCT</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719042-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241225170554-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse post-transplantation remains a catastrophic event with poor prognosis. The incidence of relapse has remained unchanged over the last three decades despite an evolving understanding of the immunobiology of the graft-versus leukemia effect and the immune escape mechanisms that lead to post-HCT relapse. The approach &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719288/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Transforming Households with Refraction and Innovative Financial Technology (THRIFT): study protocol for a randomised controlled trial of vision interventions and online banking among the elderly in Kurigram</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719288-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Presbyopia, difficulty in seeing close-ups, affects a billion people globally. Mobile financial services (MFS) have been mandated since January 2021 for Bangladesh government social safety net payments, including old age allowance (OAA) and widow allowance (WA). We report the protocol for the Transforming Households with Refraction and Innovative Financial Technology randomised trial assessing the impact on the use of online banking of providing presbyopic safety net &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719410/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Ten-Year Outcomes and Predictors of Mortality Following Catheter Ablation of Ventricular Tachycardia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719410-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Within an all-comer patient cohort, estimated 10-year all-cause mortality following VT ablation is 39.4%. Mortality after VT ablation is worse in patients with SHD and highest for patients with ischemic heart disease. Acute procedural success plays a major role in predicting VT recurrence and long-term &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39719500/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241225170611&amp;v=2.18.0.post9&#43;e462414">Thoughts for the future</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39719500-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241225170611-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.npr.org/2026/01/01/1198920729/embedded-the-black-gate">Embedded: The Black Gate</a></h1>
  <div class="date-author">
    
    <span class="date">2024-12-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-npr-org-2026-01-01-1198920729-embedded-the-black-gate/">
    
    
    
    
    
      
    
    In the Xinjiang region of western China, the government has rounded up and detained hundreds of thousands of Uyghurs and other Muslim ethnic groups. Many haven&rsquo;t been heard from in years, and more still are desperately searching for their families. Western governments have called this crackdown a cultural genocide and a possible crime against humanity.<!-- raw HTML omitted --><!-- raw HTML omitted -->In this episode, the first of a three-part series from Embedded, NPR correspondent Emily Feng tells the story of one of those people. For years, a Uyghur man named Abdullatif Kucar had no idea what has happened to his wife and young &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

